ThermoGenesis Holdings Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor ThermoGenesis Holdings te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks

Apr 17

Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?

Dec 15

ThermoGenesis EPS misses by $0.27, misses on revenue

Nov 12

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat ThermoGenesis Holdings onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:THMO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2024	10	-15	-5	-4	N/A
12/31/2023	9	-18	-5	-4	N/A
9/30/2023	10	-14	-4	-3	N/A
6/30/2023	10	-14	-5	-4	N/A
3/31/2023	10	-14	-5	-4	N/A
12/31/2022	10	-11	-8	-7	N/A
9/30/2022	10	-10	-7	-6	N/A
6/30/2022	11	-9	-7	-6	N/A
3/31/2022	10	-11	-7	-7	N/A
12/31/2021	9	-11	-7	-7	N/A
9/30/2021	9	-12	-9	-9	N/A
6/30/2021	8	-12	-11	-11	N/A
3/31/2021	8	-14	-16	-16	N/A
12/31/2020	10	-16	-14	-14	N/A
9/30/2020	10	-18	-12	-12	N/A
6/30/2020	11	-17	-9	-9	N/A
3/31/2020	13	-12	-4	-3	N/A
12/31/2019	13	-9	-3	-3	N/A
9/30/2019	14	-13	-4	-3	N/A
6/30/2019	13	-13	-4	-4	N/A
3/31/2019	11	-39	-8	-7	N/A
12/31/2018	10	-40	-8	-7	N/A
9/30/2018	10	-32	-10	-9	N/A
6/30/2018	10	-32	-11	-9	N/A
3/31/2018	11	-6	-8	-7	N/A
12/31/2017	13	-6	N/A	-8	N/A
9/30/2017	14	-9	N/A	-7	N/A
6/30/2017	15	-29	N/A	-7	N/A
3/31/2017	14	-32	N/A	-6	N/A
12/31/2016	14	-40	N/A	-8	N/A
9/30/2016	13	-38	N/A	-10	N/A
6/30/2016	12	-19	N/A	-10	N/A
3/31/2016	13	-17	N/A	-10	N/A
12/31/2015	14	-11	N/A	-9	N/A
9/30/2015	15	-15	N/A	-8	N/A
6/30/2015	16	-15	N/A	-11	N/A
3/31/2015	16	-15	N/A	-11	N/A
12/31/2014	16	-12	N/A	-9	N/A
9/30/2014	16	-10	N/A	-10	N/A
6/30/2014	16	-9	N/A	-8	N/A
3/31/2014	16	-8	N/A	-7	N/A
12/31/2013	17	-7	N/A	-5	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van THMO boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van THMO naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van THMO naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van THMO naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van THMO naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van THMO naar verwachting over 3 jaar hoog zal zijn

ThermoGenesis Holdings Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates fall by 25%

Forecast breakeven date moved forward to 2023

Price target decreased to US$1.00

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2022

Price target decreased to US$6.00

Recent updates

ThermoGenesis Holdings, Inc. announced delayed 10-Q filing

ThermoGenesis Holdings, Inc. Receives A Notice of Default from Boyalife Group (USA), Inc

ThermoGenesis Holdings Receives Notice from Nasdaq Due to Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity for Continued Listing Under Nasdaq’s Listing Rule 5550(b)(1)

ThermoGenesis Holdings, Inc. announced delayed 10-Q filing

ThermoGenesis Holdings Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Listing Rule 5550(b)(1)

ThermoGenesis Holdings, Inc. announced delayed annual 10-K filing

New major risk - Share price stability

ThermoGenesis Holdings Receives Letter from The Nasdaq Stock Market Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

ThermoGenesis Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.288 million.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

ThermoGenesis Holdings, Inc. to Report Q3, 2023 Results on Nov 13, 2023

ThermoGenesis Holdings, Inc., Annual General Meeting, Dec 14, 2023

Consensus revenue estimates fall by 25%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Holdings, Inc. to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Holdings, Inc. to Report Q1, 2023 Results on May 15, 2023

It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target decreased to US$1.00

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Holdings, Inc. to Report Q1, 2023 Results on Nov 10, 2022

ThermoGenesis Holdings, Inc., Annual General Meeting, Dec 15, 2022

ThermoGenesis Holdings, Inc. has completed a Composite Units Offering in the amount of $2.0547 million.

Nasdaq Grants Extension to ThermoGenesis Holdings to Regain Compliance

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

ThermoGenesis reports Q2 results

ThermoGenesis Holdings, Inc. to Report Q4, 2022 Results on Aug 11, 2022

ThermoGenesis Holdings, Inc. Announces Board Changes

ThermoGenesis Holdings, Inc. Board Changes

ThermoGenesis Holdings, Inc. to Report Q1, 2022 Results on May 19, 2022

ThermoGenesis Holdings, Inc. announced delayed 10-Q filing

Forecast to breakeven in 2022

Price target decreased to US$6.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 3Q 2020)

Is ThermoGenesis Holdings (NASDAQ:THMO) Using Too Much Debt?

Thermogenesis Awards Nih Sbir Phase I Grant to Develop Key Cell Processing Disposable for Quintessence Automated Manufacturing of Gene-Engineered Autologous Cell (Geac) Therapies

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.38 loss per share (vs US$1.02 loss in 2Q 2020)

Is ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?

Consensus revenue estimates fall to US$9.94m

First quarter 2021 earnings released: US$0.21 loss per share (vs US$1.11 loss in 1Q 2020)

When Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?

Consensus revenue estimates fall to US$13.6m

Full year 2020 earnings released: US$2.60 loss per share (vs US$3.36 loss in FY 2019)

ThermoGenesis Holdings, Inc. to Report Q4, 2020 Results on Mar 17, 2021

Here's Why ThermoGenesis Holdings (NASDAQ:THMO) Can Afford Some Debt

New 90-day high: US$3.85

Thermogenesis Holdings, Inc. Launches A Gmp Compliant Automated Cell Washing and Reformulation System -- Pxp™-Lavare -- for Car-T Manufacturing

New 90-day high: US$2.73

New 90-day low: US$2.10

Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?

Earnings beat expectations, revenue disappoints

Third quarter 2020 earnings released: US$0.37 loss per share

ThermoGenesis EPS misses by $0.27, misses on revenue

ThermoGenesis Holdings, Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: US$2.55

New 90-day low: US$3.24

New 90-day low - US$3.66

First half earnings released

ThermoGenesis Holdings, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten